Funding and disclosure
Who pays for this publication, how much of it, and what they get for it. Sponsorship buys a labelled advertising unit and nothing else.
The Compound Journal is funded by advertising and by nothing else. There is no paywall, no subscription, no membership tier, no events business, no consultancy arm, no affiliate revenue and no reader data business. We hold no accounts, set no tracking cookies and run no third-party analytics.
Who advertises
Four organisations. All four are named here, permanently, and each appears in labelled units marked Advertisement or Sponsored.
- Janoshik Analytical — an independent peptide testing laboratory in the Czech Republic.
- PeptideMeter — an independent peptide testing and batch-verification service.
- Sigma-Aldrich — a supplier of reference standards, analytical reagents and protected amino acids.
- GL Biochem (Shanghai) Ltd. — a peptide synthesis company.
Two of those four are organisations this publication covers editorially, and two are organisations it has criticised in print during periods in which they were paying us. We think naming them is the only defensible arrangement: a reader who knows who funds us can discount us accordingly, and a reader who does not know cannot.
The wall
- Sponsors see no editorial copy before publication. Not their own coverage, not anybody’s.
- Sponsors have no input into what is covered, by whom, or in what terms.
- No advertiser has ever been given advance notice of coverage concerning them, favourable or otherwise.
- Advertising is sold by placement and period, never against a subject, a keyword or a named company.
- There are no sponsored articles, no advertorial, no "in partnership with" features, and no native units designed to resemble editorial.
- Every unit is labelled on every appearance. A unit that could be mistaken for editorial has failed, whatever it earned.
- No vendor in the dossier programme advertises in the Journal, and no dossier is available for purchase, review or amendment by its subject.
The paired unit, disclosed
Readers with sharp eyes will have noticed that a Janoshik unit is always followed immediately by a GL Biochem unit. That is a commercial arrangement between those two advertisers and the Journal, agreed as a package: a testing laboratory adjacent to a synthesis house. We disclose it because an unexplained pattern in advertising placement looks like an editorial statement, and this one is not.
What we refuse
- Advertising from any company in our vendor dossier programme.
- Advertising for prescription medicines directed at consumers.
- Advertising that makes a therapeutic claim, or that implies a research-use-only compound is suitable for human use.
- Any placement conditional on coverage, on the removal of coverage, or on advance sight of coverage.
- Affiliate arrangements of any kind, including on links inside advertising units.
Costs we carry ourselves
The vendor dossier programme buys material at retail and pays independent laboratories at commercial rates. That is the single largest line in our editorial budget and it is funded from general revenue, not from any sponsor. Congress registration and travel are paid by the Journal; we accept no industry hospitality. Where we report a study or a session that was industry-supported, the piece says so.
Contributor declarations
Nobody who writes for the Journal accepts speaking fees, consultancy, honoraria, travel or equity from a pharmaceutical manufacturer, a compounding pharmacy, a testing laboratory or a research-chemical vendor. Where a contributor has a prior relationship with an organisation we cover, it is stated on their contributor page and in the piece.
If this changes
Any change to how the Journal is funded — a new sponsor, a subscription, a change to the wall — will be announced in an editor’s letter and recorded on this page with a date. If you are reading a version of this page that has not changed since 1 July 2026, nothing has changed.
Questions about any of this: standards@compoundjournal.com.